HEALTH/MEDICINE

Seeing Ahead: Allergan Inc. recently told analysts in New York that it expects a rough 1990 in part because of public warnings about the adverse side effects of extended-wear contact lenses. The Food and Drug Administration recently recommended that those using such lenses wear them for no longer than seven days before removing them for a night because studies indicate that wearing them continuously for longer periods could be harmful.

The Irvine-based eye care company is also facing an increased competition. “The trends in the eye care market and the continuing impact of competitive lens care systems have led to difficulties during 1989 which will likely continue into 1990,” Gavin Herbert, Allergan chairman and chief executive officer, told analysts.

Allergan stock has been sliding since Nov. 9, when Herbert made his remarks. On Wednesday, the company’s stock closed at $15.875, down 25 cents. On the day before Herbert’s presentation to analysts, by contrast, Allergan closed at $18.625.

Earnings for the third quarter rose 14% to $29.4 million; revenue was up 9% to $206.4 million.